Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083

By afschroeder • July 2, 2025

Brown TT, Arao RF, Warsi M, Phanuphak N, Vasconcelos R, Oyedele T, Sullivan PA, Hanscom B, Rooney JF, Rinehart AR, McCauley M, Grinsztejn B, Landovitz RJ. Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083. Clin Infect Dis. 2025 Jul 1:ciaf221. doi: 10.1093/cid/ciaf221. Epub ahead of print. PMID: 40590452.

Tags: Bone mineral density, Cabotegravir, HIV Pre-Exposure Prophylaxis, Infectious Diseases, Publications, tenofovir disoproxil fumarate

Comparing sampling approaches for assessing sub-national vaccination coverage: a pilot study in Central African Republic and the Democratic Republic of Congo

Kasonga JN, Hoff NA, Merritt S, Fandema E, Nkamba DM, Zanga-Goumet HE, Bobo E, Tangney S, Mafuta E, Bangelesa F, Babakazo P, Kokolomami J, Stahley[...]

Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

Glascock A, Maguire C, Phan HV, Lydon EC, Schaenman J, Calfee CS, Melamed E, Greenland J, Corry DB, Kheradmand F, Baden LR, Sekaly R, McComsey[...]

Detection of Marburg Virus Antibodies 25 Years After Outbreak in Watsa, Democratic Republic of the Congo

Merritt S, Mukadi PK, Kompany JP, Halbrook M, Musene K, Martin SA, Beya M, Tambu M, Wong TAS, Muyembe-Tamfum JJ, Kaba DK, Lehrer AT, Kindrachuk[...]